
SCC stands for squamous cell carcinoma. It is a cancer of the flat surface cells that line skin and the places where skin meets the moist tissues of the body.
When people talk about SCC in Connemaras, they usually mean eye SCC. It shows up at the rim where the clear cornea meets the white of the eye, on the thin pink tissue over the white of the eye, on the eyelids, and on the third eyelid, the pink membrane in the inner corner of the eye. Third-eyelid tumours can be hard to see and may be large before anyone notices them.
What you might notice: a raised, rough, pink mass around the eye, a sore on an eyelid that looks a bit like a burn, bleeds off and on, and forms scabs, or thick yellow discharge from the eye. Only a biopsy, a small sample looked at under a microscope, can confirm it, because other things can look very similar. Summer sores, for example, can mimic SCC. If you see something like this, it is a vet eye exam, promptly, not a wait-and-see.
Left untreated, eye SCC grows into the tissues around it. It can destroy the eye, invade the eye socket and sinuses, and, less commonly, spread to lymph nodes and beyond. It mostly affects adult and older horses. In one study across two clinics, the average age at diagnosis was about 14 years, with a range from 5 to 28.
SCC also occurs in other places: lips and nose, head and neck, around the anus, and the genitalia. Those are not the same story as eye SCC. Genital SCC is strongly linked to a papillomavirus, while the genetic risk described below applies to the eye. Do not treat “SCC” as one single condition, and do not assume a test for eye SCC tells you anything about SCC anywhere else.
Eye SCC has no single cause. Three things come together: sunlight, pigment, and genes.
Sunlight is the central environmental factor. Ultraviolet light damages DNA in the cells of the eye’s surface. The body has repair crews for that damage, and one of the crew members is a protein called DDB2. Its job is to spot UV-damaged DNA so it can be repaired.
The genetic part is a small change in the DDB2 gene, on chromosome 12, known as c.1013C>T, or T338M for short. In laboratory tests, the changed protein fails to bind UV-damaged DNA properly. It is a loss-of-function change: the repair crew member does not do its job. The change was first found in Haflingers in 2017, where it was strongly linked to SCC at the rim of the eye, and it has since been found in Belgian Drafts, Rocky Mountain Horses, and Connemaras.
Pigment matters too. Horses with little or no pigment in the skin around their eyes are at greater risk, and case studies have reported chestnut and grey coats more often than expected among affected horses. But those are associations in case series, not proof that a coat colour causes cancer. The researchers are clear that how pigment and the DDB2 change interact has not yet been properly investigated. What matters most is the pigment around the individual eye, not the colour of the horse’s body. And geldings show up more often than mares and stallions in most case series, though whether that is hormones or simply that geldings tend to be older and kept differently is not settled.
Here is where I want to be careful, because the Connemara evidence is real but thin, and a breeder who overstates it will mislead people.
There is no population figure for how often Connemaras develop SCC. Nobody has counted it. What exists is three pieces of evidence:
First, in the key 2020 paper, exactly two affected Connemaras were genotyped, both geldings, aged 7 and 17, and both carried two copies of the DDB2 change. Two cases is a start, not a verdict.
Second, in 86 Connemara DNA samples held in a bank, not examined for disease, the DDB2 change showed up in about 22% of gene copies. About 7% of those ponies carried two copies and about 29% carried one copy. That is similar to Haflingers, a breed known to be at raised risk. But it tells us how common the variant is, not how many ponies get cancer. Those are different questions.
Third, at one French eye clinic, Connemaras made up about 17% of eye SCC cases while being under 1% of that clinic’s total eye caseload. France has the largest Connemara population outside Ireland, and clinic caseloads reflect who gets referred, not how common a disease is in the whole breed. It is suggestive, not proof.
The authors of the 2020 paper concluded the variant is likely an important risk factor in Connemaras and recommended testing, while saying themselves that a larger study of affected and unaffected ponies is needed. That is the honest position, and it is the position of this article: Connemaras are a breed in which DDB2 matters, and how often Connemaras actually develop SCC is unknown.
This is the most important section in the article, because it is where the DDB2 test is most often misunderstood.
The DDB2 change is described as recessive. But recessive here means recessive risk, not recessive disease.
So a horse with two copies is at greatly increased risk. It is not certain to get cancer. A horse with no copies can still get SCC. A horse with one copy is, on the standard reading of the evidence, not at increased risk compared with a clear horse, though one 2025 Haflinger study suggested carriers might carry some extra risk. That finding is unreplicated and not studied in Connemaras, so I am calling it an open question, not a fact.
A DDB2 carrier, a horse with one copy, is most likely at no extra risk itself. What matters for both is the same practical question: can this mating produce a foal with two copies? For DDB2, that foal is at greatly increased risk of an eye cancer that usually appears around age 14, long after breeding decisions are made. Both are worth avoiding. They are not the same thing, and breeding plans should not treat them as if they were.
No breed society policy on SCC was found for Connemaras, from either the ACPS or the CPBS. There is no registry requirement, no published Connemara breeding rule, and no heritability figure. What follows is what the published evidence supports, plus plain reasoning where the evidence runs out. I have marked the reasoning so you can tell the difference.
1. Test breeding stock for DDB2. The UC Davis Veterinary Genetics Laboratory offers the test, and other commercial labs do too. It uses mane or tail hair roots, or blood. I am not quoting a price here because I did not verify one; check with the lab. The 2020 paper supports testing in Connemaras to help with mate selection and with looking after at-risk horses. Test the Connemara parent in a cross: the variant travels with that parent. A Thoroughbred parent is not automatically clear, so if the goal is no foals with two copies, test the mare too when she will be bred to a carrier or two-copy Connemara stallion.
2. Avoid matings that can produce a foal with two copies. This is the clearest published recommendation, from the Haflinger work: take each animal’s DDB2 result into account and exclude high-risk matings. The arithmetic is simple:
3. Do not remove all carriers from breeding. With about 29% of sampled Connemaras carrying one copy, excluding every carrier would cut nearly a third of the breeding population out of a small breed, and no published work supports that. The recommendation is to exclude high-risk matings, not carrier animals. A carrier can be bred, bred to a tested-clear mate. That is the practical rule, and it keeps genetic diversity while producing no two-copy foals.
4. A horse that has actually developed eye SCC. No published rule was found on whether such a horse should be bred. Here is what can honestly be said. Test the horse, because having the disease does not prove it carries two copies. A two-copy horse passes the change to every foal, so mate choice, a tested-clear mate only, and telling buyers matter most. The horse needs lifelong eye care and sun protection whatever you decide, and the decision belongs with the treating vet and eye specialist, not with a rule in an article. And remember: because SCC usually appears around 14, a stallion can sire many foals before ever showing disease. A clean eye exam on a young horse proves nothing about its genes.
5. Test relatives, keep records, tell buyers. Testing the parents, full siblings, and offspring of any two-copy or affected horse follows naturally from the mate-selection advice. Keep each horse’s DDB2 result, with notes on eye pigment and dated eye-exam findings, and record any SCC diagnosis, where it was, at what age, and how it was treated. There is no registry requirement to disclose DDB2 results, but telling mare owners and buyers voluntarily is good practice and lets people make informed decisions.
6. What not to do. Do not select for or against a coat colour as a stand-in for DDB2 risk. Do not use the eye test to make claims about genital or skin SCC. Do not describe a two-copy horse as certain to get cancer, or a clear horse as unable to get SCC. Both are false.
The evidence-backed measures are simple, and they are the same ones vets recommend for any horse with sun-sensitive eyes:
Sunscreen on pink skin is often mentioned in general horse-care writing. No study was found measuring whether it prevents SCC in horses, so I am not presenting it as proven prevention. Masks, shade, and exams are the trio with backing behind them.
Diagnosis needs a biopsy. Treatment is always vet- and eye-specialist-led. Surgery to remove the tumour is the usual starting point, most often combined with another treatment, freezing, radiation, or chemotherapy applied to the area, because tumours often come back after surgery alone. Tumours confined to the third eyelid can often be cured by removing that membrane. For large or invasive tumours, removing the eye is sometimes the life-saving option. Affected horses can develop new tumours at other sites in the eye after successful treatment, which is why monitoring is lifelong, not a one-time fix. Newer treatments are being studied in small numbers of horses, but this article is not the place to recommend any of them for an individual horse. That conversation belongs with your vet.
I would rather say this plainly than let the article sound more certain than the science is:
None of that is a reason to ignore SCC. It is a reason to test, to avoid two-copy foals, to protect eyes from the sun, and to keep records, without pretending we know more than we do. The Connemara is a small breed with a closed studbook. We cannot afford to throw away a third of it over a misunderstood test, and we cannot afford to ignore a real, testable risk either. Testing, thoughtful mating choices, and honest disclosure let us do neither.
Sources: Crausaz et al., “DDB2 Genetic Risk Factor for Ocular Squamous Cell Carcinoma Identified in Three Additional Horse Breeds,” Genes, 2020; Bellone et al., International Journal of Cancer, 2017; UC Davis Center for Equine Health, “Ocular Squamous Cell Carcinoma”; OMIA entry 000735, Ocular squamous cell carcinoma; Schäfer et al., Schweizer Archiv für Tierheilkunde, 2023; Quatember et al., Animals, 2025; Dugan et al., JAVMA, 1991. Simplified here for general readers; this article is general information, not veterinary advice for an individual horse.
— Lisa Martin, Ballymoon Farm, Browns Valley, California
For more of our latest photos and inspiration, follow along on instagram at @instapony_.
© Redbud Ranch 2020 | Connemara Sport Horses and Ponies | photos by Lisa Martin |
terms & Condtions |
privacy Policy
Intentionally Bred with People in Mind
Browns Valley, CA
+ Show / Hide Comments
Share to: